CreatorsPublishersAdvertisers
View more in
Medical & Biotech

BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy

Benzinga
 2021-07-21

Cover picture for the articleBioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy candidate for severe hemophilia A. Data were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. Five-year and four-year post-treatment follow-up of the 6e13 vg/kg...

www.benzinga.com

Comments / 0

Comments / 0